Indaptus Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price
Indaptus Therapeutics, Inc. (INDP) had Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price of $2.38 per share as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice · last filed 2026-08-13
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $2.38.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $2.38.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $7.69.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $9.24.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price as first filed |
|---|---|---|
| 2026-06-30 | $2.38 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $2.38 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $7.69 10-K · filed 2026-03-17 | |
| 2025-09-30 | $9.24 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $9.24 10-Q · filed 2025-08-13 | |
| 2024-12-31 | $43.12 10-K · filed 2026-03-17 | $1.54 10-K · filed 2025-03-13 |
| 2024-09-30 | $1.97 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $1.97 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $1.74 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $1.70 10-K · filed 2025-03-13 | |
| 2023-09-30 | $1.70 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $1.67 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $1.62 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $4.04 10-K · filed 2024-03-13 | |
| 2022-09-30 | $4.04 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $4.67 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $4.82 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $8.80 10-K · filed 2023-03-17 | |
| 2021-08-04 | $8.87 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |